nirmatrelvir

URI: https://gptkb.org/entity/nirmatrelvir
GPTKB entity
Statements (30)
Predicate Object
gptkbp:instanceOf gptkb:chemical_compound
antiviral drug
gptkbp:approvalYear 2021
gptkbp:approvedBy gptkb:FDA
gptkb:EMA
gptkbp:ATCCode gptkb:J05AX31
gptkbp:CASNumber gptkb:2628280-40-8
gptkbp:combines gptkb:ritonavir
gptkbp:component gptkb:Paxlovid
gptkbp:developedBy gptkb:Pfizer
gptkbp:drugClass protease inhibitor
gptkbp:eliminationHalfLife 6 hours
gptkbp:excretion urine
gptkbp:hasMolecularFormula C23H32F3N5O4
https://www.w3.org/2000/01/rdf-schema#label nirmatrelvir
gptkbp:IUPACName (1R,2S,5S)-N-[(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
gptkbp:legalStatus prescription only
gptkbp:mechanismOfAction SARS-CoV-2 main protease inhibitor
gptkbp:metabolism minimal
gptkbp:molecularWeight 499.5 g/mol
gptkbp:pregnancyCategory Not assigned (US)
gptkbp:routeOfAdministration oral
gptkbp:sideEffect diarrhea
hypertension
muscle pain
altered taste
gptkbp:synonym gptkb:PF-07321332
gptkbp:usedFor treatment of COVID-19
gptkbp:bfsParent gptkb:Paxlovid
gptkbp:bfsLayer 5